Netarsudil Suppliers & Bulk Manufacturers
Available Forms: Eye Drops
Available Strengths: 0.02%
Reference Brands: Rhopressa (USA)
Category:
Opthalmology
Netarsudil is available in Eye Drops
and strengths such as 0.02%.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Netarsudil is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Netarsudil can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Netarsudil ophthalmic solution (0.02%), marketed under the brand name Rhopressa, is an FDA-approved therapy indicated for the treatment of glaucoma and ocular hypertension. Approved in December 2017, it belongs to the class of Rho-kinase (ROCK) inhibitors and is designed to lower elevated intraocular pressure (IOP), a major risk factor for optic nerve damage and progressive vision loss in primary open-angle glaucoma.
Netarsudil works by increasing aqueous humor outflow through the trabecular meshwork and reducing episcleral venous pressure, effectively decreasing IOP. This targeted mechanism helps prevent optic nerve fiber damage and minimizes the risk of permanent visual field loss. The medication is administered as a 0.02% ophthalmic solution, typically once daily, providing convenient and effective management of eye pressure for patients.
Rhopressa therapy emphasizes the importance of adherence to prescribed dosing, regular ophthalmologic follow-up, and careful monitoring of intraocular pressure. It has been shown to be generally well-tolerated, with a safety profile consistent with topical ocular therapies. By combining efficacy, ease of use, and a targeted mechanism, netarsudil represents a significant advancement in the management of glaucoma and ocular hypertension, supporting long-term visual preservation and improved patient outcomes.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing